NCT04354818 (CORIA) is a clinical trial in HIV-1-infection, sponsored by Kirby Institute.

Who is sponsoring NCT04354818?

NCT04354818 is sponsored by Kirby Institute.

What condition does NCT04354818 study?

NCT04354818 studies HIV-1-infection, Cancer, Primary Immune Deficiency Disorder, Immunosuppression Disorders, COVID-19.

Is NCT04354818 still recruiting?

NCT04354818 is currently status unknown. Last updated 1 September 2021.

Last reviewed 2021-09-01 · How we verify

NCT04354818: CORIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)

Status unknown Last updated 1 September 2021

What this trial tests

trial in HIV-1-infection in 27 participants. Status unknown.

Timeline

11 May 2020

Primary endpoint
27 April 2022

27 April 2022

Quick facts

Lead sponsor	Kirby Institute
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	27
Start date	11 May 2020
Primary completion	27 April 2022
Estimated completion	27 April 2022
Sites	11 locations across Australia

Conditions studied

HIV-1-infection — all drugs for HIV-1-infection →
Cancer — all drugs for Cancer →
Primary Immune Deficiency Disorder — all drugs for Primary Immune Deficiency Disorder →
Immunosuppression Disorders — all drugs for Immunosuppression Disorders →

Sponsor

Kirby Institute

Who can join

18 and older, any sex, with HIV-1-infection or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CORIA is an observational cohort study of immunosuppressed populations who test positive for COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated with other immunosuppressive therapy, primary immunodeficiency and recipients of a solid organ transplant. Participants will have routine clinical data collected with optional baseline collection and storage of a blood sample for storage . The study will be conducted in up to 30 sites within Australia.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
Vivarelli S, Falzone L, Grillo CM, Scandurra G, et al · · 2020 · cited 63× · PMID 32785162 · DOI 10.3390/cancers12082237
COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response.
Desai A, Mohammed TJ, Duma N, Garassino MC, et al · · 2021 · cited 44× · PMID 34473192 · DOI 10.1001/jamaoncol.2021.4083
Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.
Copertino DC, Casado Lima BC, Duarte RRR, Powell TR, et al · · 2022 · cited 21× · PMID 33734021 · DOI 10.1080/07391102.2021.1901144
Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia.
Dharan NJ, Sasson SC, Ahlenstiel G, Andersen CR, et al · · 2023 · PMID 37910527 · DOI 10.1371/journal.pone.0289907
Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia
Dharan NJ, Sasson SC, Ahlenstiel G, Andersen CR, et al · · 2023 · DOI 10.1101/2023.08.17.23293358

Verify or expand the search:

Other recruiting trials for HIV-1-infection

Currently open trials in the same condition.

NCT07293559 — Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States · recruiting
NCT06919016 — A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1- · Phase 1 · active not recruiting
NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV · Phase 2 · recruiting
NCT06774872 — Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Succes · Phase 2 · recruiting
NCT06890988 — Ending the Epidemic Interventions in the Dental Setting - UH3 · NA · recruiting

Other Kirby Institute trials

Trials by the same sponsor.

NCT07145736 — Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical · Phase 4 · recruiting
NCT06220370 — PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised. · not yet recruiting
NCT05415267 — Immunosuppression and COVID-19 Boosters · Phase 3 · recruiting
NCT05144776 — Evaluation of Hepatitis B Virus (HBV) DNA Test As Point of Care Tool · completed
NCT04014179 — Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04354818 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kirby Institute
Last refreshed: 1 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04354818.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing